In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles

Erik Rytting, Michael Bur, Regis Cartier, Thierry Bouyssou, Xiaoying Wang, Michael Krüger, Claus Michael Lehr, Thomas Kissel

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The development and performance of a novel nanoparticle-based formulation for pulmonary delivery has been characterized chronologically through the particle preparation process, in vitro testing of drug release, biocompatibility, degradation, drug transport in cell culture, and in vivo bronchoprotection studies in anaesthetised guinea pigs. This study demonstrates excellent agreement of the in vitro and in vivo experiments undertaken to prove the feasibility of the design, thereby serving as an example highlighting the importance of in vitro test methods that predict in vivo performance. Nanoparticles were prepared from the newly designed negatively-charged polymer poly(vinyl sulfonate-co-vinyl alcohol)-g-poly(d,l-lactic-co-glycolic acid) loaded with salbutamol free base. Average particle sizes of blank and drug-loaded nanoparticles prepared at the various stages of the investigations were between 91 and 204 nm; average zeta potential values were between - 50.1 and - 25.6 mV. Blank nanoparticles showed no significant toxicity, and no inflammatory activity was detected in Calu-3 cells. Sustained release of salbutamol from the nanoparticles was observed for 2.5 h in vitro, and a prolonged effect was observed for 120 min in vivo. These results demonstrate good agreement between in vitro and in vivo tests and also present a promising foundation for future advancement in nanomedicine strategies for pulmonary drug delivery.

Original languageEnglish (US)
Pages (from-to)101-107
Number of pages7
JournalJournal of Controlled Release
Volume141
Issue number1
DOIs
StatePublished - Jan 4 2010
Externally publishedYes

Fingerprint

Albuterol
Nanoparticles
Pharmaceutical Preparations
Nanomedicine
Lung
Particle Size
Polymers
Guinea Pigs
Cell Culture Techniques
In Vitro Techniques

Keywords

  • Biocompatibility
  • In vitro-in vivo correlation
  • Nanoparticle
  • Pulmonary drug delivery
  • Salbutamol

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. / Rytting, Erik; Bur, Michael; Cartier, Regis; Bouyssou, Thierry; Wang, Xiaoying; Krüger, Michael; Lehr, Claus Michael; Kissel, Thomas.

In: Journal of Controlled Release, Vol. 141, No. 1, 04.01.2010, p. 101-107.

Research output: Contribution to journalArticle

Rytting, Erik ; Bur, Michael ; Cartier, Regis ; Bouyssou, Thierry ; Wang, Xiaoying ; Krüger, Michael ; Lehr, Claus Michael ; Kissel, Thomas. / In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. In: Journal of Controlled Release. 2010 ; Vol. 141, No. 1. pp. 101-107.
@article{6b8f8422ce7c42fa941e39d3335ddc6b,
title = "In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles",
abstract = "The development and performance of a novel nanoparticle-based formulation for pulmonary delivery has been characterized chronologically through the particle preparation process, in vitro testing of drug release, biocompatibility, degradation, drug transport in cell culture, and in vivo bronchoprotection studies in anaesthetised guinea pigs. This study demonstrates excellent agreement of the in vitro and in vivo experiments undertaken to prove the feasibility of the design, thereby serving as an example highlighting the importance of in vitro test methods that predict in vivo performance. Nanoparticles were prepared from the newly designed negatively-charged polymer poly(vinyl sulfonate-co-vinyl alcohol)-g-poly(d,l-lactic-co-glycolic acid) loaded with salbutamol free base. Average particle sizes of blank and drug-loaded nanoparticles prepared at the various stages of the investigations were between 91 and 204 nm; average zeta potential values were between - 50.1 and - 25.6 mV. Blank nanoparticles showed no significant toxicity, and no inflammatory activity was detected in Calu-3 cells. Sustained release of salbutamol from the nanoparticles was observed for 2.5 h in vitro, and a prolonged effect was observed for 120 min in vivo. These results demonstrate good agreement between in vitro and in vivo tests and also present a promising foundation for future advancement in nanomedicine strategies for pulmonary drug delivery.",
keywords = "Biocompatibility, In vitro-in vivo correlation, Nanoparticle, Pulmonary drug delivery, Salbutamol",
author = "Erik Rytting and Michael Bur and Regis Cartier and Thierry Bouyssou and Xiaoying Wang and Michael Kr{\"u}ger and Lehr, {Claus Michael} and Thomas Kissel",
year = "2010",
month = "1",
day = "4",
doi = "10.1016/j.jconrel.2009.08.021",
language = "English (US)",
volume = "141",
pages = "101--107",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles

AU - Rytting, Erik

AU - Bur, Michael

AU - Cartier, Regis

AU - Bouyssou, Thierry

AU - Wang, Xiaoying

AU - Krüger, Michael

AU - Lehr, Claus Michael

AU - Kissel, Thomas

PY - 2010/1/4

Y1 - 2010/1/4

N2 - The development and performance of a novel nanoparticle-based formulation for pulmonary delivery has been characterized chronologically through the particle preparation process, in vitro testing of drug release, biocompatibility, degradation, drug transport in cell culture, and in vivo bronchoprotection studies in anaesthetised guinea pigs. This study demonstrates excellent agreement of the in vitro and in vivo experiments undertaken to prove the feasibility of the design, thereby serving as an example highlighting the importance of in vitro test methods that predict in vivo performance. Nanoparticles were prepared from the newly designed negatively-charged polymer poly(vinyl sulfonate-co-vinyl alcohol)-g-poly(d,l-lactic-co-glycolic acid) loaded with salbutamol free base. Average particle sizes of blank and drug-loaded nanoparticles prepared at the various stages of the investigations were between 91 and 204 nm; average zeta potential values were between - 50.1 and - 25.6 mV. Blank nanoparticles showed no significant toxicity, and no inflammatory activity was detected in Calu-3 cells. Sustained release of salbutamol from the nanoparticles was observed for 2.5 h in vitro, and a prolonged effect was observed for 120 min in vivo. These results demonstrate good agreement between in vitro and in vivo tests and also present a promising foundation for future advancement in nanomedicine strategies for pulmonary drug delivery.

AB - The development and performance of a novel nanoparticle-based formulation for pulmonary delivery has been characterized chronologically through the particle preparation process, in vitro testing of drug release, biocompatibility, degradation, drug transport in cell culture, and in vivo bronchoprotection studies in anaesthetised guinea pigs. This study demonstrates excellent agreement of the in vitro and in vivo experiments undertaken to prove the feasibility of the design, thereby serving as an example highlighting the importance of in vitro test methods that predict in vivo performance. Nanoparticles were prepared from the newly designed negatively-charged polymer poly(vinyl sulfonate-co-vinyl alcohol)-g-poly(d,l-lactic-co-glycolic acid) loaded with salbutamol free base. Average particle sizes of blank and drug-loaded nanoparticles prepared at the various stages of the investigations were between 91 and 204 nm; average zeta potential values were between - 50.1 and - 25.6 mV. Blank nanoparticles showed no significant toxicity, and no inflammatory activity was detected in Calu-3 cells. Sustained release of salbutamol from the nanoparticles was observed for 2.5 h in vitro, and a prolonged effect was observed for 120 min in vivo. These results demonstrate good agreement between in vitro and in vivo tests and also present a promising foundation for future advancement in nanomedicine strategies for pulmonary drug delivery.

KW - Biocompatibility

KW - In vitro-in vivo correlation

KW - Nanoparticle

KW - Pulmonary drug delivery

KW - Salbutamol

UR - http://www.scopus.com/inward/record.url?scp=70849084242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70849084242&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2009.08.021

DO - 10.1016/j.jconrel.2009.08.021

M3 - Article

VL - 141

SP - 101

EP - 107

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -